A senescence-related signature for predicting the prognosis of breast cancer: A bioinformatics analysis

Breast cancer is a heterogeneous disease with diverse prognosis and treatment outcomes. Current gene signatures for prognostic prediction are limited to specific subtypes of breast cancer. Cellular senescence is a state of irreversible cell cycle arrest that affects various physiological and pathological processes. This study aimed to develop and validate a senescence-related signature for predicting the prognosis of breast cancer patients. We retrieved 744 senescence-associated genes from the SeneQuest database and analyzed their expression profiles in 2 large datasets of breast cancer patients: The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). We used univariate Cox regression analysis, least absolute shrinkage and selection operator (LASSO) regression, and multivariate Cox regression analysis to derive a 29-gene senescence-related risk signature. The risk signature was significantly associated with disease-specific survival (DSS), clinical characteristics, molecular subtypes, and immune checkpoint genes expressions in both datasets. The risk signature also stratified high-risk and low-risk patients within the same clinical stage and molecular subtype. The risk signature was an independent prognostic factor for breast cancer patients. The senescence-related signature may be a useful biomarker for predicting prognosis and immunotherapy response of breast cancer patients. The risk signature may also guide adjuvant chemotherapy decisions, especially in hormone receptor positive (HR+) and human epidermal growth factor receptor type 2 (HER2)− subtypes.

[1]  B. Baradaran,et al.  Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study , 2020, Diagnostics.

[2]  Bin Wang,et al.  Ectodermal‐neural cortex 1 as a novel biomarker predicts poor prognosis and induces metastasis in breast cancer by promoting Wnt/β‐catenin pathway , 2020, Journal of cellular and molecular medicine.

[3]  Amy M. Sitapati,et al.  Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  C. Schmitt,et al.  Cellular Senescence: Defining a Path Forward , 2019, Cell.

[5]  B. Bay,et al.  Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression. , 2019, Cancer letters.

[6]  Vanessa M. Hubbard-Lucey,et al.  Immunotherapy and targeted therapy combinations in metastatic breast cancer. , 2019, The Lancet. Oncology.

[7]  Brock Humphries,et al.  Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway. , 2018, Cancer letters.

[8]  Xiu-zhi Guo,et al.  Methylation of NBPF1 as a novel marker for the detection of plasma cell-free DNA of breast cancer patients. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[9]  M. Demaria,et al.  Hallmarks of Cellular Senescence. , 2018, Trends in cell biology.

[10]  Soyoung Lee,et al.  Senescence-associated reprogramming promotes cancer stemness , 2017, Nature.

[11]  Juan Zhang,et al.  Guanylate-binding protein 2 regulates Drp1-mediated mitochondrial fission to suppress breast cancer cell invasion , 2017, Cell Death and Disease.

[12]  L. Emens.  Breast Cancer Immunotherapy: Facts and Hopes , 2017, Clinical Cancer Research.

[13]  B. Kennedy,et al.  Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse. , 2017, Cancer discovery.

[14]  G. Hu,et al.  Biomarker Studies in Early Detection and Prognosis of Breast Cancer. , 2017, Advances in experimental medicine and biology.

[15]  X. Wang,et al.  Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. , 2016, Cancer cell.

[16]  M. Krem,et al.  MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling , 2016, Oncotarget.

[17]  Carsten Denkert,et al.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.

[18]  Zhongmei Zhou,et al.  Transforming growth factor-beta increases breast cancer stem cell population partially through upregulating PMEPA1 expression. , 2016, Acta biochimica et biophysica Sinica.

[19]  Toby C. Cornish,et al.  PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. , 2016, Human pathology.

[20]  Chiara Benedetto,et al.  Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis , 2015, PloS one.

[21]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[22]  Jean-François Dartigues,et al.  Estimating and comparing time‐dependent areas under receiver operating characteristic curves for censored event times with competing risks , 2013, Statistics in medicine.

[23]  T. Spector,et al.  DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker , 2012, Carcinogenesis.

[24]  J. Rahnenführer,et al.  Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response , 2014, Breast Cancer.

[25]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[26]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[27]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[28]  S. Paik,et al.  Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[30]  J. Campisi,et al.  The senescence-associated secretory phenotype: the dark side of tumor suppression. , 2010, Annual review of pathology.

[31]  Robert B Livingston,et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.

[32]  L. J. Veer,et al.  Metastatic Potential of T1 Breast Cancer can be Predicted by the 70-gene MammaPrint Signature , 2010, Annals of Surgical Oncology.

[33]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Judith Campisi,et al.  Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor , 2008, PLoS biology.

[35]  A. Witteveen,et al.  Converting a breast cancer microarray signature into a high-throughput diagnostic test , 2006, BMC Genomics.

[36]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  L. Elmore,et al.  Evasion of a Single-Step, Chemotherapy-Induced Senescence in Breast Cancer Cells: Implications for Treatment Response , 2005, Clinical Cancer Research.

[38]  Szu-Yu Chen,et al.  Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. , 2005, Cancer research.